Skip to main content
MedWatcherBeta

Loading research and source information…

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease for Crohn’s disease: evidence and status · MedWatcher